


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (1):



as a single tautomer, a mixture of tautomers, a single stereoisomer, a mixture of stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt or solvate thereof; wherein:

R^1 , R^2 and R^3 at each occurrence is independently selected from amino, aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfonyl, sulfoxido, thiol, thioureido, and ureido; and

R^4 is selected from hydrogen, heteroalkyl, heteroaryl, and hydrocarbyl.

2. (Currently amended) A composition according to Claim 1 wherein heteroalkyl is selected from aminohydrocarboyl (*i.e.*, ~~$\text{NH}-\text{C}(=\text{O})-\text{Hy}$~~), amido (*i.e.*, ~~$\text{C}(=\text{O})-\text{NH}_2$~~), carboxylic acid (*i.e.*, ~~COOH~~), cyano (*i.e.*, ~~CN~~), dihydrocarbylamido,

~~(i.e., $\text{C}(=\text{O})\text{N}(\text{Hy})(\text{Hy})$), dihydrocarbylamino (i.e., $\text{N}(\text{Hy})(\text{Hy})$),~~
di(hydrocarbyl)phosphido, formyl ~~(i.e., $\text{C}(=\text{O})\text{H}$)~~, hydrocarboyl ~~(i.e., $\text{C}(=\text{O})\text{Hy}$)~~,
hydrocarboxyloxy ~~(i.e., $\text{O}-\text{C}(=\text{O})\text{Hy}$)~~, hydrocarbylamino ~~(i.e., $\text{NH}-\text{Hy}$)~~, hydrocarbyloxy
~~(i.e., $\text{O}-\text{Hy}$)~~, hydrocarbyloxycarbonyl ~~(i.e., $\text{C}(=\text{O})-\text{O}-\text{Hy}$)~~, hydrocarbylsiloxy,
hydrocarbylsilylamino, hydrocarbylsulfido ~~(i.e., $\text{S}-\text{Hy}$)~~, hydrocarbylthio,
hydrocarbylamido ~~(i.e., $\text{C}(=\text{O})\text{N}(\text{H})(\text{Hy})$)~~, isothiocyanate, *N*-heterocycle,
perfluorohydrocarbyl, thiocyanate, and hydrocarbyl substituted with one or more groups
selected from alkylamino, amino, aminosulfinyl, aminosulfonyl, azido, dialkylamino,
halogen, heteroalkyl, heteroaryl, hydrazinyl, hydroxyl, nitro, nitroso, phosphate,
phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl,
sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfonyl, sulfoxido, thiol,
thioureido, and ureido.

3. (Currently amended) The composition of Claim 1 where hydrocarbyl is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene, and aryl, where

alkyl, alkenyl and alkynyl ~~is~~ are each optionally substituted with one or more Hy^1 groups selected from cycloalkyl, cycloalkylene and aryl, where each Hy^1 group is optionally substituted with one or more Hy^2 groups selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene, and aryl; and

cycloalkyl, cycloalkylene and aryl ~~is~~ are each optionally substituted with one or more Hy^2 groups selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene and aryl;

provided that when Hy^2 is selected from alkyl, alkenyl or alkynyl, then Hy^2 may be substituted with one or more Hy^3 groups selected from cycloalkyl, cycloalkylene and aryl, where each Hy^3 group is optionally substituted with one or more Hy^4 groups selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene, and aryl, and

when Hy² is selected from cycloalkyl, cycloalkylene and aryl then Hy² is optionally substituted with one or more Hy⁴ groups; and

further provided that aryl includes an aryl ring fused to a non-aromatic hydrocarbocyclic ring.

4. (Currently amended) The composition of ~~Claims 1-3~~ Claim 1 wherein R¹ at each occurrence is hydrogen.

5. (Currently amended) The composition of ~~any one of Claims 1-4~~ Claim 1 wherein R⁴ is hydrogen.

6. (Currently amended) The composition of ~~any one of Claims 1-4~~ Claim 1 wherein R⁴ is C₁-C₈ hydrocarbonyl.

7. (Currently amended) The composition of ~~any one of Claims 1-6~~ Claim 1 wherein R² is hydrogen.

8. (Currently amended) The composition of ~~any one of Claims 1-6~~ Claim 1 wherein R² is selected from lower alkyl and lower haloalkyl.

9. (Currently amended) The composition of any one of ~~Claims 1-6~~ Claim 1 wherein R² is amino.

10. (Currently amended) The composition of any one of ~~Claims 1-6~~ Claim 1 wherein R² is heterocycle.

11. (Currently amended) The composition of ~~Claims any one of 1-6~~
Claim 1 wherein R^2 is N-heterocycle.

12. (Currently amended) The composition of ~~Claims any one of 1-6~~
Claim 1 wherein R^2 is hydrocarbyl.

13. (Currently amended) The composition of ~~any one of Claims 1-12~~
Claim 1 wherein R^3 is hydrogen.

14. (Currently amended) The composition of ~~any one of Claims 1-12~~
Claim 1 wherein R^3 is selected from phenyl and substituted phenyl.

15. (Original) The composition of Claim 14 wherein R^3 is phenyl substituted with one or more substituents selected from amino, aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfonyl, sulfoxido, thiol, thioureido, and ureido.

16. (Original) The composition of Claim 14 wherein R^3 is phenyl substituted with one or more substituents selected from hydroxyl, lower alkoxy, lower alkyl,

17. (Currently amended) The composition of ~~Claims 1-12~~ Claim 1 wherein R^3 is heteroalkyl.

18. (Currently amended) The composition of ~~Claim 1-12~~ Claim 1 wherein R^3 is selected from amino, hydrocarbylamino and dihydrocarbylamino.


19. (Original) The composition of Claim 18 wherein R^3 is hydrocarbylamino where hydrocarbyl is aralkyl.

20. (Original) The composition of Claim 18 wherein R^3 is hydrocarbylamino where hydrocarbyl is alkyl.

21. (Original) The composition of Claim 18 wherein R^3 is amino.

22. (Currently amended) The composition of ~~Claims 1-12~~ Claim 1 wherein R^3 is hydrocarbyl.

23. (Currently amended) A compound of formula (1):



as a single tautomer, a mixture of tautomers, a single stereoisomer, a mixture of stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt or solvate thereof; wherein:


R^1 and R^2 at each occurrence is independently selected from amino, aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate,

phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfonyl, sulfoxido, thiol, thioureido, and ureido;

R^3 is selected from heterocycle, hydrogen, halogen-substituted hydrocarbyl and hydrocarbyl; and

R^4 is selected from hydrogen, heteroalkyl, heteroaryl, and hydrocarbyl.

24. (Original) A compound of formula (1):



as a single tautomer, a mixture of tautomers, a single stereoisomer, a mixture of stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt or solvate thereof; wherein:

R^1 each occurrence is independently selected from amino, aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfonyl, sulfoxido, thiol, thioureido, and ureido;

R^2 is amino;


R^3 is selected from hydrocarbyl, -O-hydrocarbyl and -S-hydrocarbyl; and

R^4 is selected from hydrogen, heteroalkyl, heteroaryl, and hydrocarbyl.

25. (Canceled)

26. (Canceled)

27. (Original) A compound of formula (1):




as a single tautomer, a mixture of tautomers, a single stereoisomer, a mixture of stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt or solvate thereof; wherein:

R^1 , R^2 and R^3 at each occurrence is independently selected from amino, aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfonyl, sulfoxido, thiol, thioureido, and ureido, with the proviso that R^1 is not hydrogen in at least one occurrence of R^1 ; and

R^4 is selected from hydrogen, heteroalkyl, heteroaryl, and hydrocarbyl.

28. (Canceled)

29. (Original) A compound of formula (2):



as a single tautomer, a mixture of tautomers, a single stereoisomer, a mixture of stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt or solvate thereof; wherein:

R^1 at each occurrence is independently selected from amino, aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfonyl, sulfoxido, thiol, thioureido, and ureido;

R^4 is selected from hydrogen, heteroalkyl, heteroaryl, and hydrocarbyl;
and

R^5 , R^6 , R^7 and R^8 at each occurrence is independently selected from heteroalkyl, heteroaryl, hydrocarbyl and hydrogen, with the proviso that R^7 and R^8 may join together to form a heterocyclic ring including the nitrogen to which they are both bonded.

30. (Currently Amended) A method of treating a hyperproliferative disorder, the method comprising: contacting a patient suffering from said hyperproliferative disorder with an effective dose of a composition according to ~~Claims~~

Express Mail No.: EV529783563US
International Application No.: PCT/CA2003/001078
International Filing Date: July 23, 2003
Preliminary Amendment

~~1-22~~Claim 1 or of a compound according to Claims 23-29Claim 23, Claim 24, Claim 27
or Claim 29.

31. (Original) The method of Claim 30, wherein said hyperproliferative disorder comprises the growth of tumor cells, neointimal hyperplasia or lymphoproliferative disorders.

32. (Canceled)

33. (Canceled)

34. (Currently Amended) The method according to Claim 30, wherein said ~~hyperproliferation~~ hyperproliferative disorder comprises angiogenesis or neovascularization.

35. (Original) The method according to Claim 34, wherein said neovascularization is ocular neovascularization.

36. (Original) The method according to Claim 35, wherein said ocular neovascularization is neovascularization of the cornea, iris, retina or choroid.

37. (Currently amended) The method according to Claim 35, wherein said ocular neovascularization is associated with age related macular degeneration or with age related diabetic retinopathy.

38. (Canceled)

39. (Original) The method according to Claim 35, further comprising the step of administering a photosensitive agent.

40. (Original) The method according to Claim 39, wherein said photosensitive agent is verteporfin.

41. (Currently amended) A method of inhibiting cell migration or invasion, the method comprising: contacting a patient suffering from a disorder resulting from said cell migration or invasion with an effective dose of a composition according to ~~Claims 1-22~~ Claim 1 or of a compound according to ~~Claims 23-28~~ Claim 23, Claim 24, Claim 27 or Claim 29.

42. (Original) The method according to Claim 41, wherein said cells are cancer cells.

43. (Original) The method according to Claim 41, wherein said cells are neutrophils.

44. (Original) The method according to Claim 41, wherein said cells are macrophages.

45. (Currently Amended) A method of inhibiting inflammation, the method comprising: contacting a patient suffering from said inflammation with an effective dose of a composition according to ~~Claims 1-22~~ Claim 1 or of a compound according to ~~Claims 23-29~~ Claim 23, Claim 24, Claim 27 or Claim 29.

Express Mail No.: EV529783563US
International Application No.: PCT/CA2003/001078
International Filing Date: July 23, 2003
Preliminary Amendment

46. (Original) The method according to Claim 45, wherein said inflammation comprises activation of macrophages.

47. (Original) The method according to Claim 46, wherein said inflammation is selected from the group consisting of rheumatoid arthritis, contact dermatitis, allergic dermatitis, and psoriasis.

48. (Original) The method according to Claim 46, wherein said inflammation is associated with asthma.

49. (Currently Amended) A method of treating renal disease, the method comprising: contacting a patient suffering from said renal disease with an effective dose of a composition according to ~~Claims 1-22~~Claim 1 or of a compound according to Claim 23, Claim 24, Claim 27 or Claim 29.~~Claims 23-29~~.

50. (Original) The method according to Claim 49, wherein said disease is caused by hypertension.

51. (Original) The method according to Claim 49, wherein said disease is not caused by hypertension.

52. (Original) The method according to Claim 49, further comprising the step of administering an ACE inhibitor.

53.-76. (Canceled)